JW Jungwoo Pharmaceutical and Oncocross Collaborate on Innovative New Drug Development Using Artificial Intelligence

Lee Sung-yeol, CEO of JW Jungwoo Pharmaceutical (right), and Kim Irang, CEO of Oncoros, are posing for a commemorative photo after signing a joint research agreement on the 24th.

[Asia Economy Reporter Lee Gwan-joo] JW Pharmaceutical announced on the 24th that it has signed a joint research agreement with AI new drug development venture company OncoCross for AI-based innovative new drug development.

Under this agreement, the two companies will use OncoCross’s AI platform ‘RAPTOR AI’ to explore new indications for the new drug pipelines being developed by JW Pharmaceutical and verify their development potential.

RAPTOR AI is an R&D platform that screens optimal indications for new drug candidates or existing developed drugs, increasing the probability of clinical success and shortening development time.

Kim I-rang, CEO of OncoCross, said, “We are pleased to establish a close cooperative relationship with JW Pharmaceutical, which possesses excellent new drug candidates,” adding, “We will strive to create many win-win cooperation cases that enhance the value of new drug pipelines of various domestic and international pharmaceutical companies through OncoCross’s AI technology.”

JW Pharmaceutical plans to further expand research cooperation with biotechs that have innovative platforms based on its own new drug development capabilities. Lee Sung-ryeol, CEO of JW Pharmaceutical, said, “We expect the joint research utilizing OncoCross’s AI-based technology to expand a patient-customized innovative new drug pipeline with new indications,” and added, “We will actively pursue an ‘open innovation’ strategy to strengthen R&D competitiveness by implementing diverse research cooperation methods with leading domestic and international research institutions and companies.”

This content was produced with the assistance of AI translation services.